Michael Jackson, PhD, MPH

Jackson_Michael_L_205x293.jpg

“I study the benefits of vaccines and the impact that vaccination programs can have on protecting communities from infectious diseases. I aim to help people make informed decisions about immunizations for themselves and their children.”

Michael L. Jackson, PhD, MPH

Associate Investigator, Kaiser Permanente Washington Health Research Institute

Biography

Michael L. Jackson, PhD, MPH, focuses on understanding how infectious diseases spread, and on designing and evaluating interventions such as vaccination programs. Dr. Jackson is the Kaiser Permanente Washington Health Research Institute (KPWHRI) principal investigator for the United States Influenza Vaccine Effectiveness (US Flu VE) Network. Using information from five sites across the country, including Kaiser Permanente Washington, this network aims to provide ongoing evaluations of the U.S. influenza vaccination program. Dr. Jackson uses data from this network to study influenza vaccine effectiveness, to estimate the burden of disease caused by influenza, and to advance the methodology of vaccine effectiveness studies.

In addition, Dr. Jackson is using data collected by the US Flu VE Network to build a simulation model for the spread of influenza, with a specific focus on understanding when new strains of the influenza virus can out-compete existing strains. This work, funded by the National Institutes of Health, aims to improve our ability to correctly choose which strains of the influenza virus to include in seasonal influenza vaccines. He also uses simulation models to predict the impact of vaccination programs on the spread of infectious diseases such as Haemophilus influenzae type b (Hib) and Neisseria meningitidis.

Dr. Jackson is a co-investigator on the Vaccine Safety Datalink (VSD) Project. The VSD, a collaboration among nine U.S. managed care organizations and the Centers for Disease Control and Prevention (CDC), is the world’s premier system for post-licensure studies of vaccine safety. As a VSD co-investigator, Dr. Jackson leads studies of the safety of childhood immunizations and develops methods for using managed care data for vaccine safety studies.

While studying for his PhD at the University of Washington, Dr. Jackson was a graduate research associate with KPWHRI from 2002 to 2007, and then a postdoctoral fellow at KPWHRI from 2007 to 2008. He then spent two years as an Epidemic Intelligence Service (EIS) officer with the CDC in Atlanta. As an EIS officer, Dr. Jackson helped lead investigations of whooping cough outbreaks and of the 2009 influenza pandemic. He also designed and oversaw an enhanced surveillance system for invasive Hib disease in the U.S. during the 2008–2009 shortage of Hib vaccines. He returned to KPWHRI as an assistant investigator in 2010. He is an affiliate associate professor at the University of Washington School of Public Health.

Research interests and experience

Recent publications

Balasubramani GK, Choi WS, Nowalk MP, Zimmerman RK, Monto AS, Martin ET, Belongia EA, McLean HQ, Gaglani M, Murthy K, Jackson ML, Jackson LA, Chung JR, Spencer S, Fry AM, Patel M, Flannery B; US Flu VE Network Investigators. Relative effectiveness of high dose versus standard dose influenza vaccines in older adult outpatients over four seasons, 2015-16 to 2018-19. Vaccine. 2020 Aug 12:S0264-410X(20)31032-X. doi: 10.1016/j.vaccine.2020.08.011. Online ahead of print. PubMed

Flannery B, Meece JK, Williams JV, Martin ET, Gaglani M, Jackson ML, Talbot HK. Systematic testing for influenza and COVID-19 among patients with respiratory illness. LID - ciaa1023 [pii] LID - 10.1093/cid/ciaa1023 [doi] FAU - Flannery, Brendan AU - Flannery B Clin Infect Dis. 2020 Jul 20:ciaa1023. doi: 10.1093/cid/ciaa1023 [Epub ahead of print] PubMed

Jackson ML, Scott E, Kuypers J, Nalla AK, Roychoudury P, Chu HY. Epidemiology of respiratory syncytial virus across five influenza seasons among adults and children one year of age and older - Washington State, 2011/12 - 2015/16. LID - jiaa331 [pii] LID - 10.1093/infdis/jiaa331 [doi] J Infect Dis. 2020 Jun 19:jiaa331. doi: 10.1093/infdis/jiaa331 [Epub ahead of print] PubMed

Kim SS, Flannery B, Foppa IM, Chung JR, Nowalk MP, Zimmerman RK, Gaglani M, Monto AS, Martin ET, Belongia EA, McLean HQ, Jackson ML, Jackson LA, Patel M. Effects of prior season vaccination on current season vaccine effectiveness in the US Flu VE Network, 2012-13 through 2017-18. Clin Infect Dis. 2020 Jun 7:ciaa706. doi: 10.1093/cid/ciaa706. [Epub ahead of print]. PubMed

Chubak J, Anderson ML, Cook AJ, Murphy CC, Jackson ML, Green BB. Methodological considerations in calculating and analyzing proportion of time covered as a measure of longitudinal cancer screening adherence. Cancer Epidemiol Biomarkers Prev. 2020 May 28:cebp.0388.2020. doi: 10.1158/1055-9965.EPI-20-0388. [Epub ahead of print]. PubMed

Lewnard JA, Liu VX, Jackson ML, Schmidt MA, Jewell BL, Flores JP, Jentz C, Northrup GR, Mahmud A, Reingold AL, Petersen M, Jewell NP, Young S, Bellows J. Incidence, clinical outcomes, and transmission dynamics of severe coronavirus disease 2019 in California and Washington: prospective cohort study. BMJ. 2020 May 22;369:m1923. doi: 10.1136/bmj.m1923. PubMed

Weinmann S, Irving SA, Koppolu P, Naleway AL, Belongia EA, Hambidge SJ, Jackson ML, Klein NP, Lewin B, Liles E, Marin M, Smith N, Weintraub E, Chun C. Incidence of herpes zoster among varicella-vaccinated children, by number of vaccine doses and simultaneous administration of measles, mumps, and rubella vaccine. Vaccine. 2020 May 19. pii: S0264-410X(20)30612-5. doi: 10.1016/j.vaccine.2020.05.006. [Epub ahead of print]. PubMed

Chung JR, Flannery B, Gaglani M, Smith ME, Reis EC, Hickey RW, Jackson ML, Jackson LA, Belongia EA, McLean HQ, Martin ET, Segaloff HE, Kim SS, Patel MM. Patterns of influenza vaccination and vaccine effectiveness among young US children who receive outpatient care for acute respiratory tract illness. JAMA Pediatr. 2020 May 4:e200372. doi: 10.1001/jamapediatrics.2020.0372. [Epub ahead of print]. PubMed

Somayaji R, Neradilek MB, Szpiro AA, Lofy KH, Jackson ML, Goss CH, Duchin JS, Neuzil KM, Ortiz JR. Effects of air pollution and other environmental exposures on estimates of severe influenza illness, Washington, USA. Emerg Infect Dis. 2020;26(5):920-9. doi: 10.3201/eid2605.190599. PubMed

Chu HY, Englund JA, Starita LM, Famulare M, Brandstetter E, Nickerson DA, Rieder MJ, Adler A, Lacombe K, Kim AE, Graham C, Logue J, Wolf CR, Heimonen J, McCulloch DJ, Han PD, Sibley TR, Lee J, Ilcisin M, Fay K, Burstein R, Martin B, Lockwood CM, Thompson M, Lutz B, Jackson M, Hughes JP, Boeckh M, Shendure J, Bedford T; Seattle Flu Study Investigators. Early detection of Covid-19 through a citywide pandemic surveillance platform. N Engl J Med. 2020 Jul 9;383(2):185-187. doi: 10.1056/NEJMc2008646. Epub 2020 May 1. PubMed

 

Influenza

Mike-Jackson-flu-vaccines_1col.jpg

Flu shot Q & A: Does COVID-19 change our approach?

KPWHRI’s Michael L. Jackson, PhD, MPH, talks about influenza vaccine research in the age of the pandemic.

Research Profile

Blog-_Mike_Jackson_Profile_after_half_marathon_1_column.jpg

5 questions with an influenza and COVID-19 epidemiologist

Dr. Mike Jackson has long studied the spread of flu and effectiveness of vaccination. And now… of COVID-19 too.

Healthy Findings Blog

Covid-19-tracking-data-M.Jackson_blog_1col.jpg

How epidemiologists predict the future of COVID-19

KPWHRI’s Dr. Michael Jackson describes how better testing will improve our ability to forecast the pandemic’s path.

director's note

News_-_Man_getting_2nd_shot-1_column.jpg

Research versus COVID-19

From clinical trials to technical support, Dr. Rita Mangione-Smith describes how Kaiser Permanente Washington researchers are fighting the novel coronavirus.

KPWHRI In the Media

New program ensures high-risk patients get flu shots in the South Sound

Researchers developed a program identifying more than 2,500 patients who are most vulnerable to the flu.

K5 News, Dec 2, 2019